Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5901-5910 Newer>

CIO September 23, 2009 Kim S. Nash	The Long Road to E-Health Records Kaiser Permanente's CIO stresses physician buy-in.
CIO September 23, 2009 Maryfran Johnson	Healthy Attitude President Obama's federal stimulus package boosts the IT impact on healthcare.
Wired September 21, 2009 Brendan I. Koerner	Jamie Heywood: Forget Medical Privacy Jamie Heywood hopes consumers will in turn share medical data with one another via online communities such as PatientsLikeMe, which will anonymize the data and sell it to medical researchers and drug developers.
The Motley Fool September 24, 2009 Brian Orelli	Wyeth's Biting the Hand That Feeds It Wyeth decides to sue the Food and Drug Administration after it approved Orchid Chemicals & Pharmaceuticals' generic version of its antibiotic Zosyn.
The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
The Motley Fool September 23, 2009 Brian Orelli	Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer.
The Motley Fool September 23, 2009 Robert Steyer	Alkermes Needs Some Financial Alchemy After a string of research and marketing disappointments, the company's CEO departs.
The Motley Fool September 22, 2009 Brian Orelli	Pfizer and Wyeth Put the Horse Before the Cart The pharmas' animal-business divestiture brings them one step closer to unity.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool September 22, 2009 Brian Orelli	Nektar Tastes Sweet Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two of its compounds.
<Older 5901-5910 Newer> Return to current articles.